Physician profile
Eric O Benner
NPI 1063648343
$4,400.37
in general payments reported to CMS, 2019-2025
40 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,934 · 2020: $617 · 2021: $500 · 2022: $227 · 2023: $298 · 2024: $503 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,122.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $496.92 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $492.94 | 2019-2025 | Jardiance |
| Amgen INC. | $438.41 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals Lp | $367.14 | 2019-2024 | Airsupra, Farxiga |
| Astellas Pharma US INC | $291.48 | 2019-2024 | Veozah |
| Lilly USA, LLC | $222.92 | 2019-2025 | Kisunla, Zepbound, Mounjaro |
| Novartis Pharmaceuticals Corporation | $219.23 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $157.05 | 2019-2023 | Xarelto |
| Abbott Laboratories | $151.14 | 2019 | |
| Allergan, INC. | $151.06 | 2019-2020 | |
| Novo Nordisk INC | $147.80 | 2019-2024 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $112.30 | 2019-2024 | |
| Abbvie INC. | $100.48 | 2019-2023 | Creon, Linzess |
| Esperion Therapeutics, INC. | $95.96 | 2021 | |
| Merck Sharp & Dohme LLC | $82.95 | 2019 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Benner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.